AU2003301439A1 - Pre-organized tricyclic integrase inhibitor compounds - Google Patents

Pre-organized tricyclic integrase inhibitor compounds

Info

Publication number
AU2003301439A1
AU2003301439A1 AU2003301439A AU2003301439A AU2003301439A1 AU 2003301439 A1 AU2003301439 A1 AU 2003301439A1 AU 2003301439 A AU2003301439 A AU 2003301439A AU 2003301439 A AU2003301439 A AU 2003301439A AU 2003301439 A1 AU2003301439 A1 AU 2003301439A1
Authority
AU
Australia
Prior art keywords
inhibitor compounds
integrase inhibitor
organized
tricyclic integrase
organized tricyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003301439A
Other languages
English (en)
Other versions
AU2003301439A8 (en
Inventor
James M. Chen
Xiaowu Chen
Maria Fardis
Haolun Jin
Choung U. Kim
Laura N. Schacherer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2003301439A1 publication Critical patent/AU2003301439A1/en
Publication of AU2003301439A8 publication Critical patent/AU2003301439A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2003301439A 2002-10-16 2003-10-15 Pre-organized tricyclic integrase inhibitor compounds Abandoned AU2003301439A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41896302P 2002-10-16 2002-10-16
US60/418,963 2002-10-16
US47878303P 2003-06-16 2003-06-16
US60/478,783 2003-06-16
PCT/US2003/032866 WO2004035577A2 (en) 2002-10-16 2003-10-15 Pre-organized tricyclic integrase inhibitor compounds

Publications (2)

Publication Number Publication Date
AU2003301439A1 true AU2003301439A1 (en) 2004-05-04
AU2003301439A8 AU2003301439A8 (en) 2004-05-04

Family

ID=32110203

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003301439A Abandoned AU2003301439A1 (en) 2002-10-16 2003-10-15 Pre-organized tricyclic integrase inhibitor compounds
AU2003301306A Abandoned AU2003301306A1 (en) 2002-10-16 2003-10-16 Pre-organized tricyclic integrase inhibitor compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003301306A Abandoned AU2003301306A1 (en) 2002-10-16 2003-10-16 Pre-organized tricyclic integrase inhibitor compounds

Country Status (19)

Country Link
US (3) US20040157804A1 (enExample)
EP (1) EP1558613A2 (enExample)
JP (1) JP2006514099A (enExample)
KR (1) KR20050087787A (enExample)
CN (1) CN100374438C (enExample)
AP (1) AP1858A (enExample)
AU (2) AU2003301439A1 (enExample)
BR (1) BR0315405A (enExample)
CA (1) CA2501881A1 (enExample)
EA (1) EA011399B1 (enExample)
HR (1) HRP20050431A2 (enExample)
IS (1) IS7845A (enExample)
MX (1) MXPA05003950A (enExample)
NO (1) NO20052378L (enExample)
NZ (1) NZ539264A (enExample)
OA (1) OA13079A (enExample)
PL (1) PL377966A1 (enExample)
UA (1) UA79830C2 (enExample)
WO (2) WO2004035577A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4910500A (en) * 1999-05-19 2000-12-12 Neurosearch A/S Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
AP2005003451A0 (en) * 2003-04-28 2005-12-31 Tibotec Pharm Ltd HIV integrase inhibitors.
EP1664046B1 (en) 2003-09-19 2009-06-17 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
CA2547418A1 (en) * 2003-12-08 2005-06-23 The Research Foundation Of State University Of New York Site selectively tagged and templated molecularly imprinted polymers for sensor applications
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
CA2552520A1 (en) * 2004-01-07 2005-07-28 The Research Foundation Of State University Of New York Protein imprinted polymers with integrated emission sites
CA2562713A1 (en) * 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
CN1964975B (zh) * 2004-05-07 2011-11-30 默沙东公司 Hiv整合酶抑制剂
EP1758585A4 (en) * 2004-06-09 2009-07-22 Merck & Co Inc HIV integrase
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7745459B2 (en) 2004-09-21 2010-06-29 Japan Tobacco Inc. Quinolizinone compound and use thereof as HIV integrase inhibitor
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1888581A2 (en) * 2005-05-16 2008-02-20 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
EP1885722B1 (en) 2005-05-19 2011-11-16 Merck Canada Inc. Quinoline derivatives as ep4 antagonists
WO2007014352A2 (en) * 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of hiv
EP1909578A4 (en) * 2005-08-04 2010-07-14 Glaxosmithkline Llc INHIBITORS OF HIV INTEGRASE
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20080039487A1 (en) * 2005-12-21 2008-02-14 Gilead Sciences, Llc Processes and intermediates useful for preparing integrase inhibitor compounds
SG170795A1 (en) 2005-12-30 2011-05-30 Gilead Sciences Inc Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
CA2651579A1 (en) 2006-05-16 2007-11-29 Gilead Sciences, Inc. Integrase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
WO2009067541A2 (en) * 2007-11-20 2009-05-28 Gilead Sciences, Inc. Integrase inhibitors
CN102670628B (zh) 2008-01-25 2015-11-25 奇默里克斯公司 治疗病毒感染的方法
KR101700267B1 (ko) * 2008-07-25 2017-01-26 비이브 헬쓰케어 컴퍼니 화합물
MX2011000971A (es) * 2008-07-28 2011-06-24 Polymedix Inc Compuestos antipaludicos.
CA2744019C (en) 2008-12-11 2017-03-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
PT3617194T (pt) 2008-12-11 2023-11-27 Shionogi & Co Processos e intermediários para inibidores carbamoilpiridona da integrase do vih
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
EP2270021A1 (en) * 2009-06-18 2011-01-05 Centre National de la Recherche Scientifique Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
AU2010305805B2 (en) 2009-10-13 2014-04-03 Elanco Animal Health Ireland Limited Macrocyclic integrase inhibitors
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
JP5745869B2 (ja) * 2010-01-22 2015-07-08 富山化学工業株式会社 アルアルキル基を有する複素環化合物
HUE032860T2 (en) 2010-02-12 2017-11-28 Chimerix Inc A method for treating a virus infection
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
TWI503323B (zh) * 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
JP5739517B2 (ja) 2010-04-02 2015-06-24 ヤンセン・アールアンドデイ・アイルランド 大環状インテグラーゼ阻害剤
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
CA2856722C (en) 2011-11-30 2022-11-22 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
KR101365849B1 (ko) * 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
WO2016125048A1 (en) 2015-02-03 2016-08-11 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
CN104803905B (zh) * 2015-04-17 2017-10-10 复旦大学 一种合成异吲哚啉‑1‑酮衍生物的方法
CN107709288A (zh) * 2016-02-03 2018-02-16 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
CN109305990B (zh) * 2017-07-28 2021-02-26 四川海思科制药有限公司 一种磷酸衍生物及制备方法和用途
CN109305989B (zh) * 2017-07-28 2021-02-26 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH385846A (de) * 1960-03-31 1964-12-31 Geigy Ag J R Verfahren zur Herstellung von neuen 7-Acyl-8-hydroxy-chinolinen und ihre Verwendung als Fungizide und Bakterizide im Pflanzen- und Materialschutz
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
WO1991019721A1 (en) 1990-06-13 1991-12-26 Arnold Glazier Phosphorous produgs
ES2118069T3 (es) * 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
EP0498722B1 (fr) * 1991-02-07 1997-07-30 Roussel Uclaf Dérivés bicycliques azotés, leur procédé de préparation, les intermédiaires obtenus, leur application comme médicaments et les compositions pharmaceutiques les renfermant
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives
US5639881A (en) * 1991-11-08 1997-06-17 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis and elucidation of pyrimido (4,5-Q) quinazoline derivatives
TW304945B (enExample) * 1992-06-27 1997-05-11 Hoechst Ag
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5538988A (en) * 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
US5854275A (en) * 1996-05-16 1998-12-29 Pfizer Inc. Cyclic imide derivatives
AU4172197A (en) * 1996-09-10 1998-04-02 Pharmacia & Upjohn Company 8-hydroxy-7-substituted quinolines as anti-viral agents
WO1999007701A1 (en) * 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
EP1082121A4 (en) 1998-06-03 2003-02-05 Merck & Co Inc HIV integrase
EP1083897A4 (en) 1998-06-03 2003-01-02 Merck & Co Inc HIV INTEGRASE INHIBITORS
MXPA00012248A (es) * 1998-06-10 2003-04-25 Arena Pharm Inc Incrementadores de acetilcolina.
US6187907B1 (en) * 1998-08-31 2001-02-13 James Chen Triple helix coil template having a biologically active ligand
AU3118200A (en) 1998-12-14 2000-07-03 Merck & Co., Inc. Hiv integrase inhibitors
RU2225860C2 (ru) 1998-12-25 2004-03-20 Шионоги & Ко., Лтд. Ароматические гетероциклические соединения, обладающие активностью в отношении вич-интегразы
TR200202129T2 (tr) 1999-06-02 2003-03-21 Shionogi & Co., Ltd. Yeni ikameli propenon türevlerinin hazırlanması için prosesler.
WO2001000578A1 (en) 1999-06-25 2001-01-04 Merck & Co., Inc. 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
US6245806B1 (en) 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
WO2001027309A1 (en) * 1999-10-13 2001-04-19 Merck & Co., Inc. Hiv integrase inhibitors
US20050010048A1 (en) 2000-10-12 2005-01-13 Linghang Zhuang Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
EP1326611B1 (en) * 2000-10-12 2007-06-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
IL155089A0 (en) * 2000-10-12 2003-10-31 Merck & Co Inc Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
CA2425625A1 (en) 2000-10-12 2002-07-18 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
WO2002030970A2 (en) * 2000-10-13 2002-04-18 Bayer Aktiengesellschaft Human histone deacetylase gene
US6518767B1 (en) * 2000-10-19 2003-02-11 Schweitzer Engineering Laboratories, Inc. Line differential protection system for a power transmission line
CA2562713A1 (en) * 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds

Also Published As

Publication number Publication date
BR0315405A (pt) 2005-08-09
EA011399B1 (ru) 2009-02-27
US20090029939A1 (en) 2009-01-29
WO2004035576A2 (en) 2004-04-29
US20040157804A1 (en) 2004-08-12
AU2003301306A1 (en) 2004-05-04
CA2501881A1 (en) 2004-04-29
MXPA05003950A (es) 2005-06-17
PL377966A1 (pl) 2006-02-20
NO20052378L (no) 2005-07-18
OA13079A (en) 2006-11-10
US20040167124A1 (en) 2004-08-26
CN100374438C (zh) 2008-03-12
US7253180B2 (en) 2007-08-07
AP2005003279A0 (en) 2005-06-30
HRP20050431A2 (en) 2005-10-31
UA79830C2 (en) 2007-07-25
AP1858A (en) 2008-06-30
KR20050087787A (ko) 2005-08-31
NZ539264A (en) 2007-08-31
EP1558613A2 (en) 2005-08-03
NO20052378D0 (no) 2005-05-13
CN1726212A (zh) 2006-01-25
AU2003301439A8 (en) 2004-05-04
WO2004035577A3 (en) 2004-07-29
IS7845A (is) 2005-05-13
JP2006514099A (ja) 2006-04-27
WO2004035576A3 (en) 2004-06-24
WO2004035577A2 (en) 2004-04-29
EA200500660A1 (ru) 2005-10-27

Similar Documents

Publication Publication Date Title
AU2003301439A1 (en) Pre-organized tricyclic integrase inhibitor compounds
AUPS137402A0 (en) Novel tricyclic compounds
AU2003266949A1 (en) Compounds
AU2003301302A1 (en) Pyradazine compounds as gsk-3 inhibitors
AU2003248872A1 (en) Hiv integrase inhibitors
AU2003221098A1 (en) Oligofluorenylene compounds
AU2003290734A1 (en) Novel compounds as pharmaceutical agents
AU2003279366A1 (en) Novel compounds
AU2003277674A1 (en) Novel parp inhibitors
AU2003215635A1 (en) Thiazol-2-yl-imine compounds as pde-7 inhibitors
AU2003216859A1 (en) Amidoacetonitrile compounds
AU2003282510A1 (en) Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
AU2003222206A1 (en) Novel benzimidazole compounds
AU2003280578A1 (en) Heterocyclic compounds
AU2003236093A1 (en) Composition for preventing arteriosclerosis
HK1077304A (en) Pre-organized tricyclic integrase inhibitor compounds
AU2003251259A1 (en) Novel compounds
AU2003255834A1 (en) Luminescent compounds
AU2003291021A1 (en) Arylpyridine compounds
AU2003292667A1 (en) Benzocycloheptapyridine compounds
AU2003255322A1 (en) Compounds
AU2003275480A1 (en) Compounds
HK1091836A (en) Aza-quinolinol phosphonate integrase inhibitor compounds
AU2003226541A1 (en) Novel compounds
HK1071135A (en) Tricyclic n-acyl compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase